Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
暂无分享,去创建一个
Alexander Radbruch | Benedikt Wiestler | Martin Bendszus | Heinz-Peter Schlemmer | Wolfgang Wick | Martha Nowosielski | Georg Goebel | H. Schlemmer | W. Wick | A. Radbruch | M. Bendszus | B. Wiestler | G. Goebel | M. Nowosielski | Markus Hutterer | G. Stockhammer | M. Hutterer | Günther Stockhammer
[1] J. D. de Groot,et al. Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.
[2] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Kostron,et al. O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma , 2011, The Journal of Nuclear Medicine.
[4] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[5] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[6] M S Brown,et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab , 2011, Neurology.
[7] Paul S Mischel,et al. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.
[8] P. Wen,et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. , 2009, Neuro-oncology.
[9] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[11] T. Mikkelsen,et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan , 2009, Journal of Neuro-Oncology.
[12] Y. Kienast,et al. Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells , 2011, Clinical Cancer Research.
[13] M. Westphal,et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.
[14] D. Sargent,et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Heiland,et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma , 2011, Annals of neurology.
[16] M. Chamberlain. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series , 2012, Expert review of neurotherapeutics.
[17] G. Fuller,et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.
[18] Y. Benjamini,et al. Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.
[19] Tracy T Batchelor,et al. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. , 2010, Neuro-oncology.
[20] P. Kelly,et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. , 2009, Journal of neurosurgery.
[21] William D. Dunn,et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.
[22] M. Mrugala,et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.
[23] David Gutman,et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.
[24] M. Weller,et al. Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence , 2011, Current neurology and neuroscience reports.
[25] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[26] L. Stalpers,et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme , 2009, BMC Cancer.
[27] S. Pastorino,et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.
[28] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[29] T. Taxt,et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.
[30] P. Wen,et al. Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.